Lymphatic Fluid Biomarkers for Candidate Therapy Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional therapeutic selection lacks a sufficiently informative sample for determining therapeutic efficacy, leading to unsatisfactory response and survival rates, particularly in cancer treatment, as conventional methods rely on patient response, blood-based biomarkers, and follow-up biopsies, with lymphatic fluid traditionally unused for diagnostics.
Innovation Solution
Analyzing effluent or drain fluid proximal to a tumor for biomarkers such as proteins, nucleic acids, and epigenetic markers to determine therapeutic efficacy, using these fluids as part of the cell culture microenvironment to mimic the in vivo state for more precise analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If conventional methods (blood-based biomarkers, follow-up biopsies) are used to determine therapeutic efficacy, then the diagnostic process is simpler and less invasive, but the information obtained is insufficient for accurate therapeutic selection and efficacy assessment
Solution Approach 1:
The patent uses effluent as an intermediary fluid that carries tumor-derived biomarkers from the tumor site to a collection point. This effluent serves as a mediator that provides direct access to tumor microenvironment information without requiring invasive procedures like biopsies or relying on blood-based markers that may not reflect local tumor conditions accurately.
Solution Approach 2:
The tumor microenvironment itself provides the diagnostic information through biomarkers that are naturally shed into the effluent. The system leverages the tumor's own biological activity (cell death, protein secretion, DNA release) to generate the diagnostic signal, eliminating the need for external intervention beyond simple effluent collection.
2Measurement precision
If lymphatic fluid is collected and analyzed for biomarkers, then therapeutic efficacy can be accurately determined, but the collection and analysis process becomes more complex
Solution Approach 1:
The patent extracts specific biomarkers (proteins, nucleic acids, epigenetic markers) from the complex effluent matrix. By focusing on measuring these particular molecular indicators rather than analyzing the entire fluid composition, the system achieves precise therapeutic efficacy assessment while managing analytical complexity through targeted measurement approaches.
3Measurement precision
If effluent is used as cell culture microenvironment to mimic in vivo state, then cellular response evaluation becomes more accurate, but the culture system becomes more complex
Solution Approach 1:
The effluent serves multiple functions: it acts as both the cell culture medium and the source of diagnostic biomarkers for therapeutic efficacy assessment. This multi-functionality eliminates the need for separate in vivo models and diagnostic sampling, as the same effluent sample enables both accurate cellular response evaluation and therapeutic monitoring.
Data Source
AI summary
The present invention provides methods for using waste effluent biofluids in cell culture assays as all or part of the cell culture microenvironment. Methods of the invention contemplate that biofluids typically regarded as waste may be used in cell-based assays to achieve a cell culture microenvironment that provides a novel understanding of cellular response.